External validation and comparison of the AHA-PREVENT and pooled cohort equations for 10-year ASCVD risk prediction in a contemporary US EHR population.
作者信息
Zinzuwadia Aniket, Li Chunying, Farukhi Zareen, Giulianini Franco, Cade Brian, Chen Lin, Karlson Elizabeth, Paynter Nina, Mora Samia, Demler Olga
机构信息
Brigham & Women's Hospital, United States of America.
Massachusetts General Hospital, United States of America.
出版信息
Am Heart J Plus. 2025 Jul 16;57:100579. doi: 10.1016/j.ahjo.2025.100579. eCollection 2025 Sep.
Abstract
摘要
相似文献
1
External validation and comparison of the AHA-PREVENT and pooled cohort equations for 10-year ASCVD risk prediction in a contemporary US EHR population.美国当代电子健康记录人群中AHA-PREVENT和汇总队列方程用于10年动脉粥样硬化性心血管疾病（ASCVD）风险预测的外部验证及比较
Am Heart J Plus. 2025 Jul 16;57:100579. doi: 10.1016/j.ahjo.2025.100579. eCollection 2025 Sep.
2
Tailoring Risk Prediction Models to Local Populations.针对当地人群定制风险预测模型。
JAMA Cardiol. 2024 Nov 1;9(11):1018-1028. doi: 10.1001/jamacardio.2024.2912.
3
Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10-Year Atherosclerotic Cardiovascular Risk Prediction.用于预测10年动脉粥样硬化性心血管风险的PREVENT方程与合并队列方程的评估及比较
J Am Heart Assoc. 2025 Feb 18;14(4):e039454. doi: 10.1161/JAHA.124.039454. Epub 2025 Feb 8.
4
Cardiovascular Disease Risk Estimates in the US CKD Population Using the PREVENT Equation.使用PREVENT方程对美国慢性肾脏病患者群体进行心血管疾病风险评估。
Am J Kidney Dis. 2025 Mar 5. doi: 10.1053/j.ajkd.2025.01.012.
5
Performance of the American Heart Association's PREVENT risk score for cardiovascular risk prediction in a multiethnic population.美国心脏协会预防风险评分在多民族人群中预测心血管风险的表现。
Nat Med. 2025 Jul 4. doi: 10.1038/s41591-025-03789-2.
6
AHA PREVENT Equations and Lipoprotein(a) for Cardiovascular Disease Risk : Insights From MESA and the UK Biobank.美国心脏协会预防方程与脂蛋白（a）对心血管疾病风险的评估：来自多族裔动脉粥样硬化研究（MESA）和英国生物银行的见解
JAMA Cardiol. 2025 Jun 4. doi: 10.1001/jamacardio.2025.1603.
7
Atherosclerotic Cardiovascular Disease Risk Estimates Using the New Predicting Risk of Cardiovascular Disease Events Equations: Implications for Statin Use.使用新的心血管疾病事件风险预测方程评估动脉粥样硬化性心血管疾病风险：对他汀类药物使用的影响
Curr Cardiol Rep. 2025 Jul 2;27(1):107. doi: 10.1007/s11886-025-02244-5.
8
External validation and comparison of six cardiovascular risk prediction models in the Prospective Urban Rural Epidemiology (PURE)-Colombia study.前瞻性城乡流行病学（PURE）-哥伦比亚研究中六种心血管疾病风险预测模型的外部验证与比较
Eur J Prev Cardiol. 2025 May 12;32(7):564-572. doi: 10.1093/eurjpc/zwae242.
9
Prediction of the 10-year risk of atherosclerotic cardiovascular disease in the Korean population.预测韩国人群的动脉粥样硬化性心血管疾病 10 年风险。
Epidemiol Health. 2023;45:e2023052. doi: 10.4178/epih.e2023052. Epub 2023 May 12.
10
PREVENT Risk Score vs the Pooled Cohort Equations in MESA.MESA研究中PREVENT风险评分与合并队列方程的比较
JACC Adv. 2025 May 26;4(6 Pt 1):101825. doi: 10.1016/j.jacadv.2025.101825.
本文引用的文献
1
Statins for Primary Prevention of Cardiovascular Disease-With PREVENT, What's a Clinician to Do?他汀类药物用于心血管疾病的一级预防——面对PREVENT研究，临床医生该怎么做？
JAMA. 2024 Sep 24;332(12):961-962. doi: 10.1001/jama.2024.13887.
2
Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations.基于美国心脏协会 PREVENT 心血管风险方程的他汀类药物和抗高血压治疗适应证的预计变化。
JAMA. 2024 Sep 24;332(12):989-1000. doi: 10.1001/jama.2024.12537.
3
Enabling phenotypic big data with PheNorm.利用 PheNorm 实现表型大数据。
J Am Med Inform Assoc. 2018 Jan 1;25(1):54-60. doi: 10.1093/jamia/ocx111.
4
Identifying Patients With High Data Completeness to Improve Validity of Comparative Effectiveness Research in Electronic Health Records Data.确定数据完整性高的患者，以提高电子健康记录数据中比较有效性研究的有效性。
Clin Pharmacol Ther. 2018 May;103(5):899-905. doi: 10.1002/cpt.861. Epub 2017 Oct 10.
5
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013年美国心脏病学会/美国心脏协会心血管风险评估指南：美国心脏病学会/美国心脏协会实践指南工作组报告
Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73. doi: 10.1161/01.cir.0000437741.48606.98. Epub 2013 Nov 12.
Zotero 插件